Trial Profile
A Prospective, Observational Study on Real-world Treatment Patterns of cabazitaxel (CBZ) in Ptients (pts) with Metastatic Castration Resistant Prostate Cancer (mCRPC):CAPRISTANA Registry Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CAPRISTANA
- 21 May 2018 Results (n=189) assessing health-related quality of life effects, presented at the 113th Annual Meeting of the American Urological Association.
- 21 May 2018 Results (n=189) assessing the effectiveness and safety presented at the 113th Annual Meeting of the American Urological Association
- 13 Oct 2017 New trial record